SCHEMBL632093

SCHEMBL632093

CC(C)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
TSHR P16473 2/20 0.42
RAPGEF4 Q8WZA2 1/20 0.40
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.38
ALOX12 P18054 2/20 0.38
CYP3A4 P08684 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
RECQL P46063 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DEPTOR Q8TB45 1/20 0.37
GAA P10253 2/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
MAPT P10636 2/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12369335 0.86 RAPGEF4 (0.44) TDP1TSHRRAPGEF4ALDH1A1SMN1; SMN2
SCHEMBL10024341 0.80 TDP1 (0.55) TDP1TSHRALDH1A1SMN1; SMN2LMNA
SCHEMBL15123943 0.78 RAPGEF4 (0.47) TDP1TSHRRAPGEF4ALDH1A1LMNA
SCHEMBL30607067 0.78 TPMT (0.55) ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL28582621 0.78 TPMT (0.55) ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL18784088 0.77 ALDH1A1 (0.58) TDP1TSHRRAPGEF4ALDH1A1SMN1; SMN2
SCHEMBL17938063 0.77 TDP1 (0.38) TDP1TSHRALDH1A1LMNAALOX12
SCHEMBL631531 0.77 TDP1 (0.54) TDP1TSHRALDH1A1SMN1; SMN2LMNA
SCHEMBL5178010 0.75 ALDH1A1 (0.56) TDP1ALDH1A1SMN1; SMN2LMNAHSD17B10
SCHEMBL19700466 0.75 S1PR2 (0.45) TDP1TSHRALDH1A1LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234955-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC (US) 2023-07-27 US disclosed
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB, LLC 2023-02-23 US disclosed
US-20210309665-A1 COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT JBKLAB CO., LTD (KR) 2021-10-07 US disclosed
US-20210002287-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2021-01-07 US disclosed
US-10774085-B2 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds ARRAY BIOPHARMA INC. (US) 2020-09-15 US disclosed
US-20190211017-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2019-07-11 US disclosed
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2018-07-03 US disclosed
US-10005783-B2 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds ARRAY BIOPHARMA INC. (US) 2018-06-26 US disclosed
US-20180127427-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2018-05-10 US disclosed
US-20180127427-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2018-05-10 US disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
WO-2007064797-A2 INHIBITORS OF C-MET AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-06-07 WO disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed
WO-2003035057-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FERRING B.V. (NL) 2003-05-01 WO disclosed
WO-1998006709-A1 CYCLIC UREA COMPOUNDS, THEIR PRODUCTION AND USE AS HERBICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-19 WO disclosed
US-4500341-A PREEMERGENCE, POSTEMERGENCE HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1985-02-19 US disclosed
EP-0014880-B1 PHENOXYCARBOXYLIC ACID AMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1982-09-22 EP disclosed
EP-0014880-A1 Phenoxycarboxylic acid amides, process for their preparation and their use as herbicides BAYER AG (DE) 1980-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds COL2A1, COL1A1, IFNAR1 TDP1 630/4885TSHR 498/4885RAPGEF4 3920/4885
US-20180127427-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, P2RX7 TDP1 50/4885TSHR 2598/4885RAPGEF4 3787/4885
US-20190211017-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, P2RX7 TDP1 50/4885TSHR 2598/4885RAPGEF4 3787/4885
US-10005783-B2 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds TYMP, TYMS, P2RX7 TDP1 50/4885TSHR 2598/4885RAPGEF4 3787/4885
US-20210309665-A1 COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT NGF, OPRL1, TRPV1 TDP1 1527/4885TSHR 2090/4885RAPGEF4 709/4885
US-20230234955-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, TK1 TDP1 28/4885TSHR 3678/4885RAPGEF4 4073/4885
US-10774085-B2 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds TYMP, TYMS, P2RX7 TDP1 50/4885TSHR 2598/4885RAPGEF4 3787/4885
US-20210002287-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, P2RX7 TDP1 50/4885TSHR 2598/4885RAPGEF4 3787/4885
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, MPST, CRAT TDP1 4527/4885TSHR 4330/4885RAPGEF4 2509/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA TDP1 4583/4885TSHR 780/4885RAPGEF4 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.